KHK6640
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
0
Recruiting
0
Completed
3
Sites
11
Countries
6
Endpoints
3
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 3 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 0 of 3 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
No normalized metric codes are available for this asset.
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT02127476A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease | KHK6640 Alzheimer’s disease | prodromal AD / mild-to-moderate AD | Ph 1 | Completed | 9 | May 2017 | - | |
| NCT02377713A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease. | KHK6640 Alzheimer’s disease | mild-to-moderate AD | Ph 1 | Completed | 1 | Sep 2016 | - | |
| NCT03093519A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease | KHK6640 Alzheimer’s disease | mild-to-moderate AD | Ph 1 | Completed | 1 | Dec 2017 | - |
Showing 1-3 of 3 trials